Condition
Parapsoriasis
Total Trials
5
Recruiting
0
Active
0
Completed
3
Success Rate
60.0%-27% vs avg
Key Insights
Highlights
Success Rate
60% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 80/100
Termination Rate
40.0%
2 terminated out of 5 trials
Success Rate
60.0%
-26.5% vs benchmark
Late-Stage Pipeline
40%
2 trials in Phase 3/4
Results Transparency
33%
1 of 3 completed with results
Key Signals
1 with results60% success
Data Visualizations
Phase Distribution
5Total
P 1 (1)
P 2 (2)
P 3 (1)
P 4 (1)
Trial Status
Completed3
Terminated2
Trial Success Rate
60.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT02425826Phase 4CompletedPrimary
A Phase 4 Study of Efficacy and Safety of Apremilast in Subjects With Moderate Plaque Psoriasis.
NCT02502188Phase 1TerminatedPrimary
Phase 1 Study of CC-90005 in Healthy Subjects and Subjects With Moderate to Severe Plaque-type Psoriasis
NCT02330237Phase 2CompletedPrimary
Natural Gels for Treatment of Plaque Psoriasis
NCT00322296Phase 2TerminatedPrimary
Phase II Trial to Evaluate the Efficacy of Topical Bexarotene Gel in Patients With Parapsoriasis
NCT00106847Phase 3Completed
A Study of the Safety and Effectiveness of Infliximab in Patients With Plaque-type Psoriasis
Showing all 5 trials